Acurx Pharmaceuticals LLC (ACXP)

Currency in USD
7.030
-0.100(-1.40%)
Closed·
7.210+0.180(+2.56%)
·
ACXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.7607.350
52 wk Range
3.80040.998
Key Statistics
Prev. Close
7.03
Open
7.08
Day's Range
6.76-7.35
52 wk Range
3.8-40.998
Volume
200.51K
Average Volume (3m)
562.94K
1-Year Change
-82.85%
Book Value / Share
3.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
ACXP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
61.700
Upside
+777.67%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Acurx Pharmaceuticals LLC News & Analysis

Show more

Acurx Pharmaceuticals LLC Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals LLC Earnings Call Summary for Q2/2025

  • Q2 2025 EPS loss of $1.89, missing forecast by 950%, leading to 4.02% pre-market stock drop to $4.30
  • Net loss improved to $2.2M from $4.1M YoY; R&D expenses reduced to $500K from $1.8M; cash reserves up to $6.1M
  • CEO optimistic despite challenges; CFO highlights cash preservation with burn rate down to ~$400K monthly
  • Company anticipates partnerships, government funding opportunities, and small clinical trial in late 2025/2026
  • Risks include financial sustainability, clinical trial funding, market competition, and regulatory compliance
Last Updated: 12/08/2025, 13:44
Read Full Transcript

Compare ACXP to Peers and Sector

Metrics to compare
ACXP
Peers
Sector
Relationship
P/E Ratio
−1.1x−7.8x−0.7x
PEG Ratio
−0.020.270.00
Price/Book
3.0x3.6x2.6x
Price / LTM Sales
-44.6x3.4x
Upside (Analyst Target)
333.9%158.5%37.6%
Fair Value Upside
Unlock−8.5%5.3%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 61.700
(+777.67% Upside)

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-1.89 / -0.18
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ACXP Income Statement

People Also Watch

3.410
BIAF
+25.83%
1.820
DVLT
-13.33%
3.15
NUAI
-5.97%
8.5300
ORBS
-9.54%
156.6100
SPRB
-1.54%

FAQ

What Stock Exchange Does Acurx Pharmaceuticals LLC Trade On?

Acurx Pharmaceuticals LLC is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Acurx Pharmaceuticals LLC?

The stock symbol for Acurx Pharmaceuticals LLC is "ACXP."

What Is the Acurx Pharmaceuticals LLC Market Cap?

As of today, Acurx Pharmaceuticals LLC market cap is 10.73M.

What Is Acurx Pharmaceuticals LLC's Earnings Per Share (TTM)?

The Acurx Pharmaceuticals LLC EPS (TTM) is -10.37.

When Is the Next Acurx Pharmaceuticals LLC Earnings Date?

Acurx Pharmaceuticals LLC will release its next earnings report on 17 Nov 2025.

From a Technical Analysis Perspective, Is ACXP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Acurx Pharmaceuticals LLC Stock Split?

Acurx Pharmaceuticals LLC has split 1 times.

How Many Employees Does Acurx Pharmaceuticals LLC Have?

Acurx Pharmaceuticals LLC has 4 employees.

What is the current trading status of Acurx Pharmaceuticals LLC (ACXP)?

As of 17 Oct 2025, Acurx Pharmaceuticals LLC (ACXP) is trading at a price of 7.030, with a previous close of 7.03. The stock has fluctuated within a day range of 6.760 to 7.350, while its 52-week range spans from 3.800 to 40.998.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.